Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (NASDAQ: JAZZ) and PTC Therapeutics (NASDAQ: PTCT)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Jazz Pharmaceuticals (NASDAQ: JAZZ) and PTC Therapeutics (NASDAQ: PTCT).

Jazz Pharmaceuticals (NASDAQ: JAZZ)

RBC Capital analyst Randall Stanicky reiterated a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) on September 14 and set a price target of $210. The company’s shares closed yesterday at $151.48.

According to TipRanks.com, Stanicky is ranked 0 out of 5 stars with an average return of -11.8% and a 26.3% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Eagle Pharmaceuticals, and Flexion Therapeutics.

Currently, the analyst consensus on Jazz Pharmaceuticals is Strong Buy and the average price target is $175.71, representing a 16.0% upside.

In a report issued on August 30, Stifel Nicolaus also maintained a Buy rating on the stock with a $190 price target.
PTC Therapeutics (NASDAQ: PTCT)

In a report issued on September 14, Matthew Eckler from RBC Capital reiterated a Hold rating on PTC Therapeutics (NASDAQ: PTCT), with a price target of $15. The company’s shares closed yesterday at $19.42, close to its 52-week high of $22.

According to TipRanks.com, Eckler is a 4-star analyst with an average return of 23.4% and a 88.9% success rate. Eckler covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Abeona Therapeutics, and Puma Biotechnology.

Currently, the analyst consensus on PTC Therapeutics is Moderate Buy and the average price target is $21.67, representing an 11.6% upside.

In a report issued on September 6, Barclays also maintained a Hold rating on the stock with a $22 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.